(Ezetimibe + obicetrapib) is under clinical development by NewAmsterdam Pharma Company and currently in Phase III for Heterozygous familial hypercholesterolemia (heFH). According to GlobalData, Phase III drugs for Heterozygous familial hypercholesterolemia (heFH) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Ezetimibe + obicetrapib)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Ezetimibe + obicetrapib) overview
The fixed dose combination of ezetimibe and obicetrapib is under development for the treatment of dyslipidemia, heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD). It is administered through oral route in the form of tablet. Ezetimibe acts by targeting Niemann Pick C1 like protein 1 (NPC1L1) and obicetrapib acts by targeting CETP.
NewAmsterdam Pharma Company overview
NewAmsterdam Pharma Company (NAP), a clinical stage biotechnology company focused on the research and development of transformative therapies for cardio-renal diseases. The company is headquartered in the Netherlands.
For a complete picture of (Ezetimibe + obicetrapib)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
